Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

13 Feb 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Cancer Treatment Studies
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24526178
DOI: 10.1007/s00280-014-2404-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyPMID 24526178Read ↗

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxaneSemantic proximity Read ↗

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.Semantic proximity Read ↗

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting DNA Methylation for Treating Triple-Negative Breast CancerSemantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsSemantic proximity Read ↗

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.Semantic proximity Read ↗

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.Semantic proximity Read ↗

Assessing germline mutational profile and its clinicopathological associations in Triple Negative Breast CancerSemantic proximity Read ↗

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.